Amphenol Corporation vs AstraZeneca PLC: Strategic Comparison

This in-depth comparison examines Amphenol Corporation and AstraZeneca PLC across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amphenol Corporation on its own, evaluating AstraZeneca PLC, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amphenol Corporation and AstraZeneca PLC is widest.

On the headline numbers, Amphenol Corporation reports annual revenue of $23.1B against $58.7B for AstraZeneca PLC, while their respective market capitalizations stand at $208.6B and $254.6B. Amphenol Corporation is headquartered in United States and AstraZeneca PLC in United Kingdom, and those different home markets shape how each company competes.

Amphenol Corporation: Amphenol makes the physical connections inside electronic systems rather than the systems themselves: connectors, cable assemblies, antennas, sensors and specialty cable. Its parts sit in hyperscale data center racks, vehicle wiring and battery systems, military aircraft and satellites, industrial equipment and mobile devices. In fiscal 2025 the company reported $23.09 billion of net sales and $4.27 billion of net income, with data centers and information technology its largest end market at 36% of sales, and it employed approximately 170,000 people at the end of the year.

AstraZeneca PLC: AstraZeneca is a British-Swedish biopharmaceutical company best known to the public for the COVID-19 vaccine it developed with the University of Oxford, but most of its revenue comes from medicines for cancer, cardiovascular and metabolic disease, respiratory and immune conditions, and rare diseases. It is headquartered on the Cambridge Biomedical Campus in England and runs strategic research centres in the UK, Sweden, the United States and China; the Beijing centre announced in March 2025 was its sixth.

Amphenol Corporation and AstraZeneca PLC pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amphenol Corporation and AstraZeneca PLC.

Amphenol Corporation business model: The business model is high volume, highly specialized B2B component manufacturing. Amphenol sells hundreds of thousands of connector, cable, antenna and sensor variants to thousands of customers, and no single end market dominates: in 2025, data centers and information technology accounted for 36% of sales, industrial 19%, automotive 15%, communications networks 10%, defense 9%, mobile devices 6% and commercial aerospace 5%. That spread is deliberate. Because the company sells critical components into almost every electronics end market, a downturn in one market is usually offset by demand in another, and parts are designed into customer platforms that stay in production for years.

AstraZeneca PLC business model: AstraZeneca discovers, develops and sells prescription medicines, and the economics turn on patent-protected pricing funded by heavy research spending. It invested $14.2 billion in research and development in 2025, about a quarter of Total Revenue, and reported gross profit of $48.1 billion on cost of sales of $10.6 billion. Because most drug candidates fail, the company supplements internal discovery with licensing and acquisitions, from the $39 billion Alexion deal to the Daiichi Sankyo antibody-drug conjugate alliance, and shares development costs and profits with partners including Daiichi Sankyo, Amgen and Merck.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amphenol Corporation stack up against those of AstraZeneca PLC.

Amphenol Corporation competitive advantage: Amphenol's competitive advantage rests on switching costs and the cost of failure. A connector may cost a few cents, but if it fails the aircraft, satellite or server rack around it stops working, so buyers qualify suppliers rather than shop on price. Qualification is slow: military programs can take two to three years, automotive platforms are designed in for five to ten years, and data center server designs require extensive signal integrity testing. Once Amphenol is designed into a platform it normally stays there for the life of that platform, which is a large part of why the company held a 25.4% GAAP operating margin on $23.09 billion of fiscal 2025 sales.

AstraZeneca PLC competitive advantage: AstraZeneca's main advantage is the depth of its oncology portfolio and the Phase III evidence behind it. Tagrisso, Imfinzi, Enhertu, Lynparza and Calquence each rest on trials that changed treatment practice, and the company had more than 100 Phase III studies running at the end of 2025 after 16 positive Phase III readouts during the year. Scale matters too: $58.7 billion of Total Revenue and $14.2 billion of annual R&D spending let it fund late-stage trials that smaller biotechs cannot, which is why partners such as Daiichi Sankyo and Amgen co-develop medicines with it. Its commercial reach in emerging markets, where China alone is about 12% of revenue, is wider than that of most US-based rivals.

Future prospects matter as much as current results. The growth strategies below explain how Amphenol Corporation and AstraZeneca PLC each plan to expand from here.

Amphenol Corporation growth strategy: Amphenol's growth strategy has two parts: sell into secular demand and buy specialized suppliers. On the first, it builds high speed copper and optical interconnects for AI clusters, including the Celerity mezzanine connector family rated to 224 Gb/s PAM4 and XtremePass co-packaged copper interconnects aimed at 448G class links, plus high voltage connectors and sensors for electric vehicles, which carry more wiring and sensing content than combustion vehicles. On the second, it completed five acquisitions in 2025, including Rochester Sensors in August and Trexon in November, and closed the $10.5 billion CommScope Connectivity and Cable Solutions purchase in January 2026. Cash generated by the datacom business funds the next set of deals.

AstraZeneca PLC growth strategy: AstraZeneca's growth strategy relies on extending its existing cancer drugs into earlier stages of treatment, before the cancer spreads, which increases the number of patients who can be treated. The $39 billion acquisition of Alexion Pharmaceuticals in 2021 also took it into rare diseases, where drugs treat small patient populations, carry high prices and face little generic competition.

A closer look at the financial trajectory of Amphenol Corporation and AstraZeneca PLC rounds out the comparison.

Amphenol Corporation: Amphenol compounds through acquisition in a fragmented industry. Net sales rose from $12.55 billion in 2023 to $15.22 billion in 2024 and $23.09 billion in 2025, and net income rose from $1.93 billion to $2.42 billion and then $4.27 billion across the same three years. Fiscal 2025 produced a 25.4% GAAP operating margin, $5.4 billion of operating cash flow and $4.4 billion of free cash flow, and the company returned nearly $1.5 billion to shareholders while completing five acquisitions. The pattern is consistent: buy niche connector, cable and sensor makers, leave their management and brands in place, add purchasing scale, and fund the next deal from cash flow and investment grade debt.

AstraZeneca PLC: AstraZeneca's Total Revenue fell from $33.6 billion in 2011 to a trough of $22.1 billion in 2018 as Seroquel, Nexium and Crestor lost exclusivity. Under Pascal Soriot the company redirected spending into oncology and specialty medicines, and revenue then grew every year to $58.7 billion in 2025, with profit for the year of $10.2 billion and gross profit of $48.1 billion on cost of sales of $10.6 billion. R&D investment reached $14.2 billion in 2025, about a quarter of Total Revenue, and the $39 billion Alexion acquisition added a rare disease business the company did not have before 2021.